Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Anthony V. D'Amico, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Anthony D'Amico and Irving Kaplan.
Connection Strength

1.217
  1. Select transition zone prostate cancers may be radiocurable despite markedly elevated prostate-specific antigen levels. Radiother Oncol. 1996 Jan; 38(1):73-6.
    View in: PubMed
    Score: 0.161
  2. Does prostate brachytherapy that avoids the central zone prevent long-term urinary incontinence? Five-year results of a multi-institutional comparative cohort study. J Clin Oncol. 2011 May 20; 29(15_suppl):4665.
    View in: PubMed
    Score: 0.117
  3. Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol. 2003 Nov 01; 21(21):3979-86.
    View in: PubMed
    Score: 0.069
  4. Lack of radiation dose response for patients with low-risk clinically localized prostate cancer: a retrospective analysis. Int J Radiat Oncol Biol Phys. 2002 Aug 01; 53(5):1106-10.
    View in: PubMed
    Score: 0.064
  5. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2001 Mar 01; 49(3):679-84.
    View in: PubMed
    Score: 0.058
  6. Investigating the clinical utility of the percent of positive prostate biopsies in predicting PSA outcome following local therapy for patients with clinically localized prostate cancer. Prostate Cancer Prostatic Dis. 2000 Dec; 3(4):259-264.
    View in: PubMed
    Score: 0.057
  7. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000 Sep 13; 284(10):1280-3.
    View in: PubMed
    Score: 0.056
  8. Clinical utility of percent-positive prostate biopsies in predicting biochemical outcome after radical prostatectomy or external-beam radiation therapy for patients with clinically localized prostate cancer. Mol Urol. 2000; 4(3):171-5;discussion 177.
    View in: PubMed
    Score: 0.053
  9. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999 Jan; 17(1):168-72.
    View in: PubMed
    Score: 0.050
  10. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16; 280(11):969-74.
    View in: PubMed
    Score: 0.049
  11. Calculated prostate cancer volume greater than 4.0 cm3 identifies patients with localized prostate cancer who have a poor prognosis following radical prostatectomy or external-beam radiation therapy. J Clin Oncol. 1998 Sep; 16(9):3094-100.
    View in: PubMed
    Score: 0.049
  12. Radiation-associated morbidity in patients undergoing small-field external beam irradiation for prostate cancer. Int J Radiat Oncol Biol Phys. 1998 May 01; 41(2):257-62.
    View in: PubMed
    Score: 0.047
  13. Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter. Cancer. 1998 Jan 15; 82(2):334-41.
    View in: PubMed
    Score: 0.046
  14. Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. Int J Radiat Oncol Biol Phys. 1997 Sep 01; 39(2):335-40.
    View in: PubMed
    Score: 0.045
  15. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. Int J Radiat Oncol Biol Phys. 1997 Mar 15; 37(5):1053-8.
    View in: PubMed
    Score: 0.044
  16. Using patient-reported outcomes to assess and improve prostate cancer brachytherapy. BJU Int. 2014 Oct; 114(4):511-6.
    View in: PubMed
    Score: 0.036
  17. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72.
    View in: PubMed
    Score: 0.035
  18. Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55.
    View in: PubMed
    Score: 0.033
  19. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6.
    View in: PubMed
    Score: 0.032
  20. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Feb 10; 30(5_suppl):131.
    View in: PubMed
    Score: 0.031
  21. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer. 2008 Oct 15; 113(8):2058-67.
    View in: PubMed
    Score: 0.024
  22. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer. Cancer. 2007 Nov 15; 110(10):2210-7.
    View in: PubMed
    Score: 0.023
  23. Using patient-reported outcomes to assess prostate brachytherapy technique. J Clin Oncol. 2005 Jun; 23(16_suppl):4697.
    View in: PubMed
    Score: 0.019
  24. Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms: a potential early indicator for technology assessment? Clin Prostate Cancer. 2004 Jun; 3(1):38-42.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.